C3 and Hepatic fibrosis: In people with compensated or decompensated cirrhosis, 28 weeks of survodutide treatment led to a trend of decreasing markers of liver fibrosis including liver stiffness, ELF scores, and plasma Pro-C3 (Lawitz et al., 2024).